Loading…
Loading…
Institutional and Insider Ownership 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Profitability This table compares ADVANZ PHARMA and
Syros Pharmaceuticals (NASDAQ: SYRS - Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Analyst Ratings This is a breakdown of
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market (“Nasdaq”) and the deregistration of its common stock in order to terminate and suspend the Company's reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today.
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression did not meet its primary endpoint of complete response (CR) rate. Tamibarotene is Syr.
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
No recent filings indexed.